← Back to Search

Behavioural Intervention

Bright Light Therapy for Fatigue and Sleep Disorders in Lung Cancer Survivors

N/A
Waitlist Available
Research Sponsored by State University of New York at Buffalo
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Must have diagnosis fatigue and/or sleep disturbances
Stage I-III Non-small cell lung cancer survivors
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 weeks
Awards & highlights

Study Summary

This trial will study the effects of morning bright light therapy on fatigue, sleep, and daily activity patterns in people who have survived lung cancer.

Who is the study for?
This trial is for Stage I-III non-small cell lung cancer survivors who are 6 weeks to 3 years post-surgery and experiencing fatigue or sleep disturbances. It's not suitable for those who are clinically unstable, have bipolar disorder, seizure disorders, macular degeneration, glaucoma, or currently undergoing chemotherapy or radiation.Check my eligibility
What is being tested?
The study is testing the effectiveness of morning bright light therapy versus dim light in improving fatigue levels, sleep quality, and circadian activity rhythms among lung cancer survivors.See study design
What are the potential side effects?
While the trial does not mention specific side effects of bright light therapy, common ones may include eyestrain, headache or agitation. Dim light is considered a control with no expected active side effects.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I experience fatigue or have trouble sleeping.
Select...
I am a survivor of stage I-III non-small cell lung cancer.
Select...
I had surgery between 6 weeks and 3 years ago.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Body Weight Changes
Change in fatigue symptoms with Fatigue Severity Index from pre-test to post-test
Change in sleep quality with the Pittsburgh Sleep Quality Index from pre-test to post-test
+1 more
Secondary outcome measures
Assessement of chronotype with the Morningness versus Eveningness Questionnaire
Assessment of Environmental light with actigraphy (Actiwatch Spectrum Respironics)
Changes in Quality of Life with theFunctional Assessment of Cancer Therapy - Lung
Other outcome measures
Assessment of Visual acuity with the Snellen visual acuity chart
Daytime Somnolence

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: ExperimentalExperimental Treatment1 Intervention
Exposure to morning bright light therapy delivered with Green-Blue Re-Timer glasses for 30 minutes in the morning during one week.
Group II: Attention ControlActive Control1 Intervention
Exposure to dim light delivered with Red-Yellow Re-Timer glasses for 30 minutes in the morning during one week.

Find a Location

Who is running the clinical trial?

State University of New York at BuffaloLead Sponsor
244 Previous Clinical Trials
49,443 Total Patients Enrolled
Oncology Nursing SocietyOTHER
10 Previous Clinical Trials
485 Total Patients Enrolled

Media Library

Morning bright light therapy (Behavioural Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT02954809 — N/A
Circadian Dysregulation Clinical Trial 2023: Morning bright light therapy Highlights & Side Effects. Trial Name: NCT02954809 — N/A
Morning bright light therapy (Behavioural Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02954809 — N/A
Circadian Dysregulation Research Study Groups: Experimental, Attention Control

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this examination presently enrolling participants?

"Clinicaltrials.gov reveals that, as of this moment, this clinical trial is not accepting any new candidates; it was first posted on October 1st 2016 and last updated November 3rd 2016. However, there are currently 356 other medical studies actively enrolling participants."

Answered by AI
Recent research and studies
~2 spots leftby Mar 2025